Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elcubragistat - Lundbeck A/S

Drug Profile

Elcubragistat - Lundbeck A/S

Alternative Names: ABX-1431; ABX-1431 HCl; Lu AG06466

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abide Therapeutics
  • Developer Abide Therapeutics; Lundbeck A/S; University of Oxford
  • Class Analgesics; Antiepileptic drugs; Anxiolytics; Benzene derivatives; Esters; Fluorinated hydrocarbons; Piperazines; Pyrrolidines; Small molecules
  • Mechanism of Action Monoacylglycerol lipase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Fibromyalgia; Muscle spasticity; Neurological disorders; Partial epilepsies; Unspecified
  • No development reported Neuropathic pain; Non-ulcer dyspepsia; Pain; Post-traumatic stress disorders
  • Discontinued Gilles de la Tourette's syndrome

Most Recent Events

  • 28 Oct 2023 No recent reports of development identified for phase-I development in Post-traumatic-stress-disorders in USA (PO, Capsule)
  • 28 Jun 2023 No recent reports of development identified for phase-I development in Neuropathic-pain(In volunteers) in USA (PO, Capsule)
  • 28 Mar 2023 No recent reports of development identified for phase-I development in Neurological-disorders(In volunteers) in Belgium (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top